About Us: Management
|
| |
| C2D2 is staffed by professional scientists with more than 50 years combined biopharma drug discovery experience at both large and small organizations. The management team includes: |
| |
| |
|
|
| Terry Opgenorth, Ph.D., is currently the Co-director of C2D2 and has served as Chief Operating Officer of NeoTREX® since joining CSU Ventures™ in 2007. Prior to joining CSU Ventures, Dr. Opgenorth retired from Abbott Laboratories after an accomplished 20-year career in the Drug Discovery arm of Abbott Pharma’s Global Research and Development Organization. Most recently, he served as Divisional Vice President of Metabolic Disease Research, Antiviral Research and Target-Lead Discovery Research. Dr. Opgenorth holds a BA in Biology from Calvin College and MS and Ph.D. degrees in Physiology from University of Illinois-Urbana. |
| |
 |
| |
|
|
|
Greg Miknis, Ph.D., joined C2D2/CSU Ventures™ in February 2010. Prior to joining, Dr. Miknis worked within Pharma/Biotech research for 13 years and has been involved in almost all aspects of drug discovery. His past employers include Array Biopharma and Abbott Laboratories. Greg has numerous publications and patent applications in addition to serving as an advisor for the Boulder Innovation Center. Greg holds a BS in chemistry from the University of Wyoming, a Ph.D. in chemistry from Colorado State University and was an American Cancer Society Postdoctoral Fellow at the University of Texas. Greg’s research interests include medicinal chemistry and development of novel anti-cancer agents.
|
| |
| |
